These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 11919460)

  • 1. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
    Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
    Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
    J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Bares R; Claussen CD; Kanz L; Bokemeyer C
    Cancer; 2002 May; 94(9):2353-62. PubMed ID: 12015760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
    Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
    J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
    de Wit M; Brenner W; Hartmann M; Kotzerke J; Hellwig D; Lehmann J; Franzius C; Kliesch S; Schlemmer M; Tatsch K; Heicappell R; Geworski L; Amthauer H; Dohmen BM; Schirrmeister H; Cremerius U; Bokemeyer C; Bares R
    Ann Oncol; 2008 Sep; 19(9):1619-23. PubMed ID: 18453520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
    Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
    Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
    Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
    Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
    Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
    Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
    Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
    Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
    Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.